176 related articles for article (PubMed ID: 9593137)
21. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
Ji BH; Chen JK; Lu XZ; Wang SY; Ni GX; Hou YH; Zhou DH; Tang QK
Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
[TBL] [Abstract][Full Text] [Related]
22. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.
Lazo-Porras M; Prutsky GJ; Barrionuevo P; Tapia JC; Ugarte-Gil C; Ponce OJ; Acuña-Villaorduña A; Domecq JP; De la Cruz-Luque C; Prokop LJ; Málaga G
BMC Infect Dis; 2020 Jan; 20(1):62. PubMed ID: 31959113
[TBL] [Abstract][Full Text] [Related]
23. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Lockwood DN; Cunha Mda G
Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
[No Abstract] [Full Text] [Related]
24. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
25. A 6 week quadruple drug regimen for the treatment of multibacillary leprosy.
Pattyn S; Grillone S
Lepr Rev; 2000 Mar; 71(1):43-6. PubMed ID: 10820986
[No Abstract] [Full Text] [Related]
26. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice.
Ji B; Perani EG; Grosset JH
Antimicrob Agents Chemother; 1991 Mar; 35(3):579-81. PubMed ID: 1828136
[TBL] [Abstract][Full Text] [Related]
27. Histological resolution and bacterial clearance with pulse ROM therapy in borderline lepromatous leprosy.
Suneetha S; Reddy R
Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):53-4. PubMed ID: 11480321
[No Abstract] [Full Text] [Related]
28. Newer drugs in leprosy.
Grosset JH
Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
[TBL] [Abstract][Full Text] [Related]
29. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
30. [New WHO recommendations for the treatment of leprosy].
Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
[No Abstract] [Full Text] [Related]
31. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
[TBL] [Abstract][Full Text] [Related]
32. The activity of rifabutin against Mycobacterium leprae.
Yoder LJ; Jacobson RR; Hastings RC
Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
[TBL] [Abstract][Full Text] [Related]
33. Field trials of a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy.
Gupte MD
Lepr Rev; 2000 Dec; 71 Suppl():S77-80. PubMed ID: 11201893
[No Abstract] [Full Text] [Related]
34. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy.
Ji B; Jamet P; Perani EG; Bobin P; Grosset JH
J Infect Dis; 1993 Jul; 168(1):188-90. PubMed ID: 8257487
[TBL] [Abstract][Full Text] [Related]
35. Single lesion paucibacillary leprosy: baseline profile of the Brazilian Multicenter Cohort Study.
Martelli CM; Stefani MM; Gomes MK; Rebello PF; Peninni S; Narahashi K; Maroclo AL; Costa MB; Silva SA; Sacchetim SC; Nery JA; Salles AM; Gillis TP; Krahenbuhl JL; Andrade AL
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):247-57. PubMed ID: 11221086
[TBL] [Abstract][Full Text] [Related]
36. Activity of two doses of rifampin against Mycobacterium leprae.
Husser JA; Traore I; Daumerie D
Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):359-64. PubMed ID: 7963907
[TBL] [Abstract][Full Text] [Related]
37. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
[TBL] [Abstract][Full Text] [Related]
38. Single-dose ROM treatment for multilesion paucibacillary leprosy--further observations.
Revankar CR; Bulchand HO; Pai VV; Ganapati R
Int J Lepr Other Mycobact Dis; 2002 Mar; 70(1):37-8. PubMed ID: 12120040
[No Abstract] [Full Text] [Related]
39. The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice.
Burgos J; de la Cruz E; Paredes R; Andaya CR; Gelber RH
Lepr Rev; 2011 Sep; 82(3):253-8. PubMed ID: 22125933
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation years in leprosy patients treated with single dose alternative scheme ROM (rifampin, ofloxacin, minocycline), after seven to nine].
Diniz LM; Catabriga MD; Souza Filho JB
Rev Soc Bras Med Trop; 2010; 43(6):695-9. PubMed ID: 21181026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
